Obstetric and Neonatal Results of Pregnant Women with Hereditary Thrombophilia

INTRODUCTION: To evaluate the obstetric and neonatal outcomes of pregnant women treated for hereditary thrombophilia. METHODS: Fifty-six pregnant women who were admitted to the gynecology and obstetrics clinic between 2018 and 2019, diagnosed as having hereditary thrombophilia before pregnancy, and whose treatment (acetylsalicylic acid and low molecular weight heparin) began at pregnancy comprised the study group, and 79 healthy pregnant women without systemic disease that might affect obstetric or fetal development constituted the control group. Study data were obtained retrospectively by scanning hospital records. Demographic characteristics of both groups (age, parity, body mass index, education level), obstetric results (birth week, birth weight, preterm labor rate, low birth weight rate, delivery type) and neonatal results (1st and 5th minute Apgar scores, neonatal intensive care hospitalization rates) were compared. RESULTS: The distribution of the groups in terms of demographic characteristics was homogeneous (p>0.05). There was no difference between the groups in terms of mean birth weight, birth week, 1st minute Apgar scores, preterm labor, and neonatal intensive care hospitalization rates (p> 0.05). However, there was a significant difference between the groups in terms of low birth weight infants, 5th minute Apgar scores, and type of delivery. In the hereditary thrombophilia group, low birth weight infants, preeclampsia, and cesarean rates were higher compared with the control group, and the 5th minute Apgar scores were lower (p

Kalıtsal Trombofilili Gebelerin Obstetrik ve Neonatal Sonuçları

GİRİŞ ve AMAÇ: Bu çalışmada kalıtsal trombofili tanısıyla tedavi alan gebelerin obstetrik ve neonatal sonuçlarının değerlendirilmesi amaçlandı. YÖNTEM ve GEREÇLER: 2018-2019 tarihlerinde kadın hastalıkları ve doğum kliniğine başvuran gebelik öncesinde kalıtsal trombofili tanısı alıp tedavisi (asetilsalisilik asit ve düşük moleküler ağırlıklı heparin) başlanan ve sonrasında gebe kalan 56 gebe çalışma grubunu, obstetrik veya fetal gelişimi etkileyebilecek sistemik hastalığı olmayan 79 sağlıklı gebe ise kontrol grubunu oluşturdu. Veriler retrospektif olarak kayıtların taranmasıyla elde edildi. Her iki grubun demografik özellikleri (yaş, parite, vücut kitle indeksi, eğitim düzeyleri), obstetrik sonuçları (doğum haftası, doğum kilosu, preterm eylem oranı, düşük doğum ağırlığı oranı, doğum şekli) ve neonatal sonuçları (1. ve 5. dakika apgar skorları, neonatal yoğun bakım yatış oranları) karşılaştırıldı. BULGULAR: Grupların demografik özellikler açısından dağılımı homojendi (p>0,05). Gruplar arasında ortalama doğum kilosu, doğum haftası, 1. dakika apgar değerleri, preterm eylem ve neonatal yoğun bakım yatış oranları açısından fark yoktu (p>0,05). Ancak düşük doğum ağırlıklı bebek sayıları, 5. dakika apgar skorları ve doğum şekilleri açısından gruplar arasında anlamlı fark mevcuttu. Kalıtsal trombofili grubunda kontrol grubuna kıyasla, düşük doğum ağırlıklı bebek, preeklampsi ve sezeryan oranları daha fazla, 5. dakika apgar skorları daha düşüktü (p

PDF

___

1.Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995; 90: 725-7.

2.Hossain N, Paidas MJ. Inherited thrombophilia: diagnosis and anticoagulation treatment in pregnancy. Clin Lab Med. 2013; 33: 377-90.

3.Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999; 340: 9-13.

4.Howley HEA, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol. 2005; 192: 694-708.

5.Rodger MA, Walker MC, Smith GN, Wells PS, Ramsay T, Langlois NJ, et al. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol. 2005; 192: 694-708.

6.ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. Obstet Gynecol. 2013; 122: 706-17.

7.Simcox LE, Ormesher L, Tower C, Greer IA. Thrombophilia and Pregnancy Complications. Int J Mol Sci. 2015; 16: 28418-28.

8.Greer IA, Brenner B, Gris JC. Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine? Br J Haematol. 2014; 165: 585-99.

9.Brenner B. Clinical management of thrombophiliarelated placental vascular complications. Blood. 2004; 103: 4003-9.

10.Gerhardt A, Scharf RE, Greer IA, Zotz RB. Hereditary Risk Factors for Thrombophilia and Probability of Venous Thromboembolism During Pregnancy and the Puerperium. Blood. 2016; 128: 2343- 2349.

11.Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy and prevention of thrombosis. 9th ed: College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:e351S–418S.

12.Dugalić S, Petronijevic M, Stefanovic A, Jeremic K, Petronijevic SV, Soldatovic I, et al. The association between IUGR and maternal inherited thrombophilias: A case-control study. Medicine. 2018; 97: e12799.

13.Livrinova V, Lega MH, Dimcheva AH, Samardziski I, Isjanovska R. Factor V Leiden, Prothrombin and MTHFR Mutation in Patients with Preeclamsia, Intrauterine Growth Restriction and Placental Abruption. Open Access Maced J Med Sci. 2015; 3: 590-4.

14.Hoffmann E, Hedlund E, Perin T, Lyndrup J. Is thrombophilia a risk factor for placenta-mediated pregnancy complications? Arch Gynecol Obstet. 2012; 286: 585-9.

15.Hemsworth EM, O'Reilly AM, Allen VM, Kuhle S, Brock JAK. Association Between Factor V Leiden Mutation, Small for Gestational Age, and Preterm Birth: A Systematic Review and Meta-Analysis. J Obstet Gynaecol Can. 2016; 38: 897-908.

16.Uvuz F, Kilic S, Yilmaz N, Tuncay G, Cakar E, Yuksel B, et al. Relationship between preterm labor and thrombophilic gene polymorphism: A prospective sequential cohort study. Gynecol Obstet Invest. 2009; 68: 234-8.

17.Wang X, Bai T, Liu S, Pan H, Wang B. Association between thrombophilia gene polymorphisms and preeclampsia: a meta-analysis. PLoS One. 2014; 9:e100789.

18.Baptista FS, Bortolotto MRFL, Bianchini FRM, Krebs VLJ, Zugaib M, Francisco RPV. Can thrombophilia worsen maternal and perinatal outcomes in cases of severe preeclampsia? Pregnancy Hypertens. 2018; 11: 81-86.

19.Arachchillage DRJ, Mike Makris M. Inherited Thrombophilia and Pregnancy Complications: Should We Test? Semin Thromb Hemost. 2019; 45: 50-60.